Documents

A list of downloadable documents created during development.

Macular degeneration (age-related) - pegaptanib and ranibizumab: Novartis Ranibizumab TA155

Macular degeneration (age-related) - pegaptanib and ranibizumab: DSU Ranibizumab TA155

Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal panel decision

Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal announcement

Macular degeneration (age-related) - pegaptanib and ranibizumab: notice of appeal

Macular degeneration (age-related)- pegaptanib and ranibizumab: final appraisal determination

Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 2 (December 2007)

Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 1 (June 2007)

Macular degeneration (age-related) - pegaptanib and ranibizumab: final protocol

Macular degeneration (age-related) - pegaptanib and ranibizumab: final scope

Macular degeneration (age-related) - pegaptanib and ranibizumab: final matrix

Macular degeneration (age-related) - pegaptanib and ranibizumab: summary of consultee and commentator comments on the draft scope

Macular degeneration (age-related) - pegaptanib and ranibizumab: summary of consultee and commentator comments on the provisional matrix

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder